Day: September 11, 2024
Dupixent is the first and only biologic to achieve significant improvements in disease remission and symptoms in bullous pemphigoid positive pivotal studyStudy met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European UnionParis and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) pivotal study (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the study, five times...
Press Release: Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSU
Written by Customer Service on . Posted in Public Companies.
Dupixent phase 3 study confirms significant improvements in itch and hives for patients with CSUConfirming the results of CUPID-A, this second pivotal study in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo
More than 300,000 people in the US suffer from chronic spontaneous urticaria (CSU) that is inadequately controlled by antihistamines
Data will support regulatory resubmission in the US by year-end; if approved, Dupixent would be the first targeted therapy for CSU in a decadeParis and Tarrytown, NY, September 11, 2024. A Dupixent (dupilumab) confirmatory phase 3 study (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with...
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
Written by Customer Service on . Posted in Public Companies.
Confirming the results of Study A, this second pivotal trial in biologic-naïve patients met primary and key secondary endpoints, showing treatment with Dupixent resulted in a nearly 50% reduction in itch and urticaria activity scores compared to placebo
More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines
Data will support regulatory resubmission in the U.S. by year-end; if approved, Dupixent would be the first targeted therapy for CSU in a decade
TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent® (dupilumab) confirmatory Phase 3 trial (LIBERTY-CUPID Study C) met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve...
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
Written by Customer Service on . Posted in Public Companies.
Trial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent than placebo
Dupixent is the first medicine to show significant steroid-sparing effect in this debilitating and life-threatening disease
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S. and European Union
TARRYTOWN, N.Y. and PARIS, Sept. 11, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent® (dupilumab) pivotal trial (ADEPT) in bullous pemphigoid (BP) met the primary and all key secondary endpoints evaluating its investigational use in adults with moderate-to-severe disease. In the trial, five times more Dupixent patients achieved sustained disease remission...
Terns Announces Pricing of Upsized $150.15 Million Public Offering
Written by Customer Service on . Posted in Public Companies.
FOSTER CITY, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced the pricing of its upsized underwritten public offering of 11,919,048 shares of its common stock at a public offering price of $10.50 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,380,952 shares of its common stock at a public offering price of $10.4999 per pre-funded warrant, in each case before underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Terns, are expected...
SIMPPLE Australia Pty Ltd Launches Cutting-Edge Robots and Software into Australian and New Zealand markets at the Sydney ISSA Cleaning & Hygiene Expo 2024
Written by Customer Service on . Posted in Public Companies.
SIMPPLE Australia Pty Ltd launches SIMPPLE Robotics for the Australia and New Zealand marketsSIMPPLE Australia team at ISSA Expo 2024 SydneySYDNEY, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) — SIMPPLE Australia Pty Ltd, a subsidiary of SIMPPLE Ltd. (NASDAQ: SPPL, “SIMPPLE”, “the Company”) and a leading technology provider in the integrated facility management sector, is launching its latest line-up of robotic solutions (SIMPPLE Robotics) in the Australia and New Zealand (ANZ) market.
SIMPPLE Australia Pty Ltd is excited to unveil its latest range of advanced cleaning and multi-functional robots at the ISSA Cleaning & Hygiene Expo 2024 in Sydney, Australia. This new robotic lineup features top-of-the-line proven industry solutions, including the recently developed multi-functional robot, Gemini, all of which are integrated...